Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Umbilical Cord Derived Mesenchymal Stromal Cell(LiveKidney.Bio) in Systemic Lupus Erythematosus: NCT06737380 Clinical Landscape Report 2026
16 October 2026
NCT06737380 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Docetaxel in Non-Muscle Invasive Bladder Neoplasms: NCT06732531 Clinical Landscape Report 2026
16 October 2026
NCT06732531 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
BZE-2204 in Relapse multiple myeloma: NCT06732232 Clinical Landscape Report 2026
16 October 2026
NCT06732232 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
mRNA-1195 in Radiologically isolated syndrome: NCT06735248 Clinical Landscape Report 2026
16 October 2026
NCT06735248 clinical landscape for Radiologically isolated syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Daratumumab in Multiple Myeloma: ACTRN12624001468516 Clinical Landscape Report 2026
16 October 2026
ACTRN12624001468516 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Empasiprubart in Multiple Myeloma: NCT06742190 Clinical Landscape Report 2026
16 October 2026
NCT06742190 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dexamethasone Sodium Phosphate in Refractory Multiple Myeloma: NCT06742138 Clinical Landscape Report 2026
16 October 2026
NCT06742138 clinical landscape for Refractory Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Decitabine in Relapsing acute myeloid leukemia: NCT06741722 Clinical Landscape Report 2026
16 October 2026
NCT06741722 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Omacetaxine Mepesuccinate in Acute Myeloid Leukemia: NCT06744556 Clinical Landscape Report 2026
16 October 2026
NCT06744556 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Multiple Myeloma: NCT06744894 Clinical Landscape Report 2026
16 October 2026
NCT06744894 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BCG vaccine(Anhui Zhifei Longcom Biologic Pharmacy) in Non-Muscle Invasive Bladder Neoplasms: NCT06747455 Clinical Landscape Report 2026
16 October 2026
NCT06747455 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Cyclophosphamide in Acute Myeloid Leukemia: NCT06744504 Clinical Landscape Report 2026
16 October 2026
NCT06744504 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.